Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology.

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion, while the ...

Meanwhile, Regeneron is also looking to diversify its revenue base to reduce its dependence on Eylea for top-line growth and build an oncology franchise, which currently comprises Libtayo.

Austin, April 23, 2025 (GLOBE NEWSWIRE) -- Immunotherapy Drugs Market Size & Growth Analysis: According to SNS Insider, The Immunotherapy Drugs Market was estimated at USD 246.00 billion in 2023 ...

Patients with pathologically confirmed solid tumors were treated with ICIs consisting of anti-PD-1/PD-L1 blockade (nivolumab [Opdivo], pembrolizumab [Keytruda], atezolizumab [Tecentriq], cemiplimab ...

The biggest stories of the day delivered to your inbox.

TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...

To use and configure, check out the setup documentation. For advanced usage, check out the configuration reference and custom instrumentation API. Confused about the terminology of APM? Take a look at ...